P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Overall Survival (OS) and Progression-Free Survival (PFS) Adjusted for Treatment Crossover in the CALGB/ECOG 100104 (Alliance) Study of Lenalidomide (LEN) Versus Placebo (PBO) Maintenance After Stem Cell Transplant (SCT) for Patients With Newly Diagnosed Multiple Myeloma
Philip L. McCarthy,Sarah A. Holstein,Sin-Ho Jung,Miranda Cooper,Craig J. Gibson,Edward A. Stadtmauer,Benjamin Winograd,Paul G. Richardson +7 more
Journal ArticleDOI
Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial
Paul G. Richardson,Nancy A. Kernan,Joel A. Brochstein,Shin Mineishi,Sally Arai,Stephan A. Grupp,Eva C. Guinan,Paul L. Martin,Gideon Steinbach,Amrita Krishnan,Eneida R. Nemecek,Reggie E. Duerst,Joseph H. Antin,Leslie Lehmann,Alfred P. Gillio,Rajinder Bajwa,Maja Miloslavsky,Robin Hume,Massimo Iacobelli,Bijan Nejadnik,Alison L. Hannah,Robert J. Soiffer +21 more
Journal ArticleDOI
Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA.
Meral Beksac,Ivan Spicka,Roman Hájek,Sara Bringhen,Tomas Jelinek,Thomas Martin,Gabor Mikala,Philippe Moreau,Argiris Symeonidis,A. Rawlings,Helgi J. K. Van De Velde,Paul G. Richardson +11 more
TL;DR: In this paper , the authors showed that isatuximab plus pomalidomide (P) and dexamethasone (d; Isa-Pd) or carfilzomib (K) and d (Isa-Kd) improved progression-free survival (PFS) versus Pd or Kd in patients with relapsed and/or refractory multiple myeloma.
Journal ArticleDOI
Novel Combination Therapies for the Treatment of Relapsed/Refractory Multiple Myeloma: Current Phase I/II Combinations
Paul G. Richardson,Jacob P. Laubach,Robert L. Schlossman,Irene M. Ghobrial,Constantine S. Mitsiades,Teru Hideshima,Dharminder Chauhan,Noopur Raje,Nikhil C. Munshi,Kenneth C. Anderson +9 more
TL;DR: Clinical Lymphoma & Myeloma Supplement February 2009 Novel Combination Therapies for the Treatment of Relapsed/Refractory Multiple Myelomas: Current Phase I/II Combinations.
Journal ArticleDOI
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment
Meletios A. Dimopoulos,Joseph R. Mikhael,Evangelos Terpos,Xavier Leleu,Philippe Moreau,Joan Bladé,Jin-Soo Kim,Keith Stockerl-Goldstein,Paul G. Richardson +8 more
TL;DR: Existing data among patients with RI and RRMM across drug classes are reviewed to provide an improved understanding of available treatment options for this important population.